Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda
New modeling study shows curative treatments may be viable in low-income settings if costs are scaled and societal benefits included
-
1
Gene therapy for sickle cell disease could be cost-effective in Uganda if prices are significantly reduced.
-
2
A modeling study adapted US economic data to assess gene therapy's viability in Uganda's low-income healthcare setting.
-
3
The lifetime standard-of-care cost for sickle cell disease in Uganda is estimated at $21,877, compared to over $600,000 in the U.S.
-
4
Casgevy is identified as the more viable gene therapy option for Uganda, meeting cost-effectiveness thresholds when local costs are applied.
-
5
The study aims to help policymakers expand equitable access to gene therapy in regions with high disease burden and limited resources.
